Adult acute monocytic leukemia

Summary

Adult acute monocytic leukemia (MONDO:0000875) is a cancer and 74 clinical trials. Top therapeutic interventions include daunorubicin, mitoxantrone hydrochloride, and eltrombopag. A subtype of acute monocytic leukemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 74

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adult acute monocytic leukemia
Mondo ID	MONDO:0000875
EFO	EFO:1001933
DOID	DOID:0080149
NCIT	C8263
UMLS	C0280634
MedGen	128856
GARD	0022837
Is cancer (heuristic)	yes

Also known as: acute monocytic leukaemia · acute monocytic leukaemia of adults · acute monocytic leukemia · acute monocytic leukemia of adults · adult acute differentiated monocytic leukaemia (M5b) · adult acute differentiated monocytic leukemia (M5b) · adult acute monocytic leukemia · M5b adult acute differentiated monocytic leukaemia · M5b adult acute differentiated monocytic leukemia · M5b adult acute leukaemia · M5b adult acute leukemia

Data availability: 71 cell lines.

Disease family

This is a subtype of acute monocytic leukemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › leukemia › monocytic leukemia › acute monocytic leukemia › adult acute monocytic leukemia

Related subtypes (2): aleukemic monocytic leukemia cutis, subacute monocytic leukemia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Tipifarnib	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 74.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	34
PHASE1	27
PHASE3	5
PHASE1/PHASE2	4
Not specified	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00003190	PHASE3	COMPLETED	Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia
NCT00006363	PHASE3	COMPLETED	Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
NCT00093470	PHASE3	COMPLETED	Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
NCT01307579	PHASE3	COMPLETED	Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
NCT02085408	PHASE3	COMPLETED	Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00658814	PHASE2	ACTIVE_NOT_RECRUITING	Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
NCT01627041	PHASE2	ACTIVE_NOT_RECRUITING	Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
NCT05566054	PHASE2	RECRUITING	Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
NCT06504459	PHASE2	RECRUITING	Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
NCT07512700	PHASE2	RECRUITING	Venetoclax Combined With CACAG Regimen Versus 3+7 Regimen in the Treatment of Acute Monocytic Leukemia
NCT00027872	PHASE2	COMPLETED	Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
NCT00045435	PHASE2	COMPLETED	Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission
NCT00089388	PHASE2	TERMINATED	Cilengitide in Treating Patients With Acute Myeloid Leukemia
NCT00093418	PHASE2	COMPLETED	S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
NCT00096122	PHASE1/PHASE2	COMPLETED	Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
NCT00096148	PHASE2	TERMINATED	Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00305773	PHASE2	COMPLETED	Vorinostat in Treating Patients With Acute Myeloid Leukemia
NCT00352365	PHASE2	COMPLETED	Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
NCT00407966	PHASE2	COMPLETED	Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00462605	PHASE2	COMPLETED	MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
NCT00602771	PHASE2	COMPLETED	Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
NCT00634244	PHASE2	COMPLETED	Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00666588	PHASE2	COMPLETED	Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
NCT00673153	PHASE2	TERMINATED	Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
NCT00742625	PHASE1/PHASE2	COMPLETED	Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
NCT00795002	PHASE2	COMPLETED	Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00895934	PHASE1/PHASE2	COMPLETED	Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
NCT01093586	PHASE2	COMPLETED	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01168219	PHASE2	COMPLETED	Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
NCT01177371	PHASE2	COMPLETED	High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
NCT01235572	PHASE2	COMPLETED	Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy
NCT01253447	PHASE2	COMPLETED	AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01342887	PHASE1/PHASE2	TERMINATED	Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01349972	PHASE2	COMPLETED	Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT01361464	PHASE2	COMPLETED	Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
NCT01521936	PHASE2	TERMINATED	Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy
NCT01607645	PHASE2	TERMINATED	Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS
NCT01835288	PHASE2	WITHDRAWN	Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01870596	PHASE2	COMPLETED	Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia
NCT02029417	PHASE2	TERMINATED	Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DAUNORUBICIN	4	8
MITOXANTRONE HYDROCHLORIDE	4	5
ELTROMBOPAG	4	4
GEMTUZUMAB OZOGAMICIN	4	3
PRAVASTATIN	4	3
VORINOSTAT	4	3
CYTARABINE	4	2
ETOPOSIDE	4	2
IDARUBICIN	4	2
ALDESLEUKIN	4	1
ARSENIC TRIOXIDE	4	1
BUSULFAN	4	1
CASPOFUNGIN ACETATE	4	1
CLADRIBINE	4	1
CLOFARABINE	4	1
DECITABINE	4	1
FILGRASTIM	4	1
FLUCONAZOLE	4	1
LITHIUM CARBONATE	4	1
METFORMIN HYDROCHLORIDE	4	1
OMACETAXINE MEPESUCCINATE	4	1
TOPOTECAN HYDROCHLORIDE	4	1
ALVOCIDIB	3	18
TIPIFARNIB	3	9
ENTINOSTAT	3	2
TANESPIMYCIN	3	2
VALSPODAR	3	2
VELIPARIB	3	2
CILENGITIDE	3	1
IXAZOMIB	3	1